These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21838468)

  • 1. Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
    Abonour R; Kramer G; Suvannasankha A; Benson MD
    Amyloid; 2011 Jun; 18 Suppl 1():151. PubMed ID: 21838468
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib in systemic AL amyloidosis: a single center experience.
    Coriu D; Badelita S; Talmaci R; Dobrea C; Dogaru M; Ostroveanu D; Crisan M
    Amyloid; 2011 Jun; 18 Suppl 1():148-50. PubMed ID: 21838467
    [No Abstract]   [Full Text] [Related]  

  • 3. Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
    Moscetti A; Saltarelli F; Bianchi MP; Monarca B; De Biase L; Porrini R; Antolino G; La Verde G
    Amyloid; 2011 Jun; 18 Suppl 1():152-4. PubMed ID: 21838469
    [No Abstract]   [Full Text] [Related]  

  • 4. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
    Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
    Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
    Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
    Brunvand MW; Bitter M
    Haematologica; 2010 Mar; 95(3):519-21. PubMed ID: 19903681
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
    Roussel M; Sachchithanantham S; Gibbs SD; Venner CP; Pinney JH; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Br J Haematol; 2013 Sep; 162(6):856-8. PubMed ID: 23773011
    [No Abstract]   [Full Text] [Related]  

  • 9. Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.
    Dispenzieri A
    Leukemia; 2014 Dec; 28(12):2273-5. PubMed ID: 25492370
    [No Abstract]   [Full Text] [Related]  

  • 10. [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
    Li J; Zhao Y; Zeng LJ; Su C; Wang HH
    Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):741-4. PubMed ID: 20079210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
    Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.
    Merlini G; Palladini G
    Haematologica; 2014 Sep; 99(9):1407-9. PubMed ID: 25176981
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib in the treatment of AL amyloidosis: targeted therapy?
    Sitia R; Palladini G; Merlini G
    Haematologica; 2007 Oct; 92(10):1302-7. PubMed ID: 18024367
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
    Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
    Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis.
    Sugiyama A; Asahina M; Takeda Y; Shiojiri T; Sano K; Ikeda S; Kuwabara S
    Amyloid; 2014 Sep; 21(3):218-20. PubMed ID: 24970351
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute dyspnea from treatment of AL amyloidisis with bortezomib.
    Ghose A; Tariq Z; Taj A; Chaudhary R
    Am J Ther; 2011 Jul; 18(4):e123-5. PubMed ID: 20335791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
    Gertz MA; Dispenzieri A
    Oncology (Williston Park); 2012 Feb; 26(2):152-61. PubMed ID: 22489348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
    Landau H; Hassoun H; Bello C; Hoover E; Riedel ER; Nimer SD; Comenzo RL
    Amyloid; 2011 Jun; 18 Suppl 1():135-6. PubMed ID: 21838462
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bortezomib (Velcade). Laboratory: Millenium Pharmaceuticals Inc].
    Moreno Alvarez PJ
    Farm Hosp; 2003; 27(4):274-5. PubMed ID: 12966459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.